For example, the relatively well‐studied EML‐ALK fusion in non‐small‐cell lung cancer (Morodomi et al., 2014) or the PML‐RAR fusion in acute myelogenous leukemia (Saeed et al., 2011) is found in only 2–5% or 6–10% of these malignancies, respectively. Here, ALK is linked to acute myeloid leukemia.